Drug developer KalVista Pharmaceuticals posts Q1 revenue after new product launch

Kalvista Pharmaceuticals

11/09/2025 12:14

Overview

KalVista fiscal Q1 net product revenue at $1.4 mln from EKTERLY sales

Company received 460 patient start forms post-EKTERLY launch, indicating strong demand

Cash reserves at $191 mln, providing financial runway into 2027

Outlook

KalVista has cash runway extending into 2027

Result Drivers

EKTERLY APPROVAL - FDA approval of EKTERLY marked a significant milestone, driving immediate commercial growth

STRONG DEMAND - KalVista received 460 patient start forms post-launch, exceeding expectations and validating unmet need for EKTERLY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$1.12
Q1 Net Income
-$60.10 mln
Q1 Operating Expenses
$60.44 mln
Q1 Operating Income
-$59.01 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kalvista Pharmaceuticals Inc is $30.00, about 48.7% above its September 10 closing price of $15.39

Press Release: ID:nBwb47PW7a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)